Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
Status:
Withdrawn
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This study plans to learn more about the combination of AMG 386 and docetaxel for the
treatment of advanced urothelial cancer. Subjects are being asked to be in this research
study because they have advanced urothelial cancer which has progressed after treatment with
a platinum-based therapy.
The hypothesis is that AMG 386 will increase the historical response rate of docetaxel as a
single agent.